Study protocol for A randomized controlled trial with Rituximab for Psychotic disorder in adults (RCT-Rits) DOI Creative Commons

Susanne Bejerot,

Daniel Eklund, Hugo Hesser

и другие.

Research Square (Research Square), Год журнала: 2023, Номер unknown

Опубликована: Окт. 6, 2023

Abstract Background: The role of inflammation in the aetiology schizophrenia has gained wide attention and research on association shows an exponential growth last 15 years. Autoimmune diseases severe infections are risk factors for later development schizophrenia, elevated inflammatory markers childhood or adolescence associated with a greater adulthood, individuals have increased levels pro-inflammatory cytokines compared to healthy controls, autoimmune overrepresented schizophrenia. However, treatments anti-inflammatory agents so far doubtful clinical relevance. primary objective this study is test whether monoclonal antibody rituximab, directed against B-cell antigen CD20 ameliorates psychotic symptoms adults schizoaffective disorder examine potential mechanisms. A secondary characteristics inflammation-associated psychosis identify pre-treatment biochemical rituximab responders. third interview subset patients informants their experiences trial obtain insights that rating scales may not capture. Methods: proof-of-concept employing randomised, parallel-group, double-blind, placebo-controlled design testing effect depletion psychosis. 120 participants diagnosis spectrum disorders (SSD) (ICD-10 codes F20, F25) will receive either one intravenous infusion (1000 mg) saline. Psychiatric measures blood samples be collected at baseline, week 12, 24 post-infusion. Brief assessments also made weeks 2 7. Neuroimaging lumbar puncture, both optional, performed baseline endpoints. Approximately 40 interviewed qualitative analyses perceived changes well-being emotional qualities, addition views research. Discussion: This first RCT investigating add-on treatment unselected SSD patients. If helpful, it transform disorders. It heighten awareness immune-psychiatric reduce stigma. Trial registration: NCT05622201, EudraCT-nr 2022-000220-37 version 2.1. registered 14 th October 2022.

Язык: Английский

Association between psychiatric admissions in patients with schizophrenia and IL-6 plasma levels polygenic score DOI
Fernando Facal, Manuel Arrojo, Mario Páramo

и другие.

European Archives of Psychiatry and Clinical Neuroscience, Год журнала: 2024, Номер 274(7), С. 1671 - 1679

Опубликована: Март 16, 2024

Язык: Английский

Процитировано

5
Anhedonia as a Potential Transdiagnostic Phenotype With Immune-Related Changes in Recent-Onset Mental Health Disorders DOI Creative Commons
Paris Alexandros Lalousis,

Aanya Malaviya,

Ali Khatibi

и другие.

Biological Psychiatry, Год журнала: 2024, Номер 96(7), С. 615 - 622

Опубликована: Май 30, 2024

BackgroundChronic low-grade inflammation is observed across mental disorders and associated with difficult-to-treat-symptoms of anhedonia functional brain changes – reflecting a potential transdiagnostic dimension. Previous investigations have focused on distinct illness categories in those enduring illness, few exploring inflammatory changes. We sought to identify an signal function underlying among young people recent onset psychosis (ROP) depression (ROD).MethodResting-state magnetic resonance imaging, markers, symptoms were collected from N=108 (M age=26.2[SD 6.2]years; Female =50) participants ROP (n=53) ROD (n=55) the EU-FP7-funded PRONIA study. Time-series extracted using Schaefer atlas, defining 100 cortical regions interest. Using advanced multimodal machine learning, marker model connectivity developed classify anhedonic group, compared normal hedonic group.ResultsA repeated nested cross-validation markers classified ROP/ROD groups balanced accuracy (BAC) 63.9%, area under curve (AUC) 0.61. The produced BAC 55.2% AUC 0.57. Anhedonic group assignment was driven by higher levels Interleukin-6, S100B, Interleukin-1 receptor antagonist, lower Interferon gamma, addition within precuneus posterior cingulate.ConclusionWe identified subtype that accounted for profile connectivity. Results implications as emerging target disorders.

Язык: Английский

Процитировано

4
Study protocol for a randomized controlled trial with rituximab for psychotic disorder in adults (RCT-Rits) DOI Creative Commons

Susanne Bejerot,

Daniel Eklund, Hugo Hesser

и другие.

BMC Psychiatry, Год журнала: 2023, Номер 23(1)

Опубликована: Окт. 23, 2023

The role of inflammation in the aetiology schizophrenia has gained wide attention and research on association shows an exponential growth last 15 years. Autoimmune diseases severe infections are risk factors for later development schizophrenia, elevated inflammatory markers childhood or adolescence associated with a greater adulthood, individuals have increased levels pro-inflammatory cytokines compared to healthy controls, autoimmune overrepresented schizophrenia. However, treatments anti-inflammatory agents so far doubtful clinical relevance. primary objective this study is test whether monoclonal antibody rituximab, directed against B-cell antigen CD20 ameliorates psychotic symptoms adults schizoaffective disorder examine potential mechanisms. A secondary characteristics inflammation-associated psychosis identify pre-treatment biochemical rituximab responders. third interview subset patients informants their experiences trial obtain insights that rating scales may not capture.A proof-of-concept employing randomised, parallel-group, double-blind, placebo-controlled design testing effect depletion psychosis. 120 participants diagnosis spectrum disorders (SSD) (ICD-10 codes F20, F25) will receive either one intravenous infusion (1000 mg) saline. Psychiatric measures blood samples be collected at baseline, week 12, 24 post-infusion. Brief assessments also made weeks 2 7. Neuroimaging lumbar puncture, both optional, performed baseline endpoints. Approximately 40 interviewed qualitative analyses perceived changes well-being emotional qualities, addition views research.This first RCT investigating add-on treatment unselected SSD patients. If helpful, it transform disorders. It heighten awareness immune-psychiatric reduce stigma.NCT05622201, EudraCT-nr 2022-000220-37 version 2.1. registered 14th October 2022.

Язык: Английский

Процитировано

6
Skin-brain dialogue in auto-inflammatory diseases: a new route to biomarkers? DOI Creative Commons
Sara Matar, S. Aractingi,

R. Gaillard

и другие.

Brain Behavior & Immunity - Health, Год журнала: 2024, Номер 42, С. 100906 - 100906

Опубликована: Ноя. 9, 2024

Autoinflammatory diseases (AID) are rare systemic inflammatory disorders due to monogenic or polygenic dysfunction of innate immunity. They affect many organs including the brain and skin. The spectrum these has been rapidly expanding recently newly developed diagnostic tools. neuro-immuno-endocrine-cutaneous interactions play an important role in pathophysiology diseases. skin-brain interplay is not fully investigated AID evidence supporting bidirectional communication examined. This article provides overview current state art with cutaneous psychiatric manifestations. Elucidating dysregulation underlying promising for determining future biomarkers therapeutic options.

Язык: Английский

Процитировано

1
The association between cytokines and cognitive function in patients with major depressive disorder and controls DOI Creative Commons

Sarah E. Fromme,

Silke Joergens,

K Shwarte

и другие.

Journal of Affective Disorders, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

1
Inflammation Proteomic Profiling of Psychosis in Young Adults: findings from the ALSPAC birth cohort DOI Creative Commons
Ruby S. M. Tsang, Nicholas J. Timpson, Golam M. Khandaker

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Май 1, 2024

Abstract Psychotic disorder is associated with altered levels of various inflammatory markers in blood, but existing studies have typically focused on a few selected biomarkers, not examined specific symptom domains notably negative symptoms, and are based individuals established/chronic illness. Based data from young people aged 24 years the Avon Longitudinal Study Parents Children (ALSPAC), UK birth cohort, we associations 67 plasma immune/inflammatory proteins assayed using Olink Target 96 Inflammation panel psychotic disorder, positive (any experiences definite experiences) linear models empirical Bayes estimation. The analyses included between 2641 2854 individuals. After adjustment for age, sex, body mass index smoking correction multiple testing, upregulation CDCP1 IL-6 were consistently symptoms while was additionally MMP-10. Negative highest number (n=11), including cytokines, chemokines growth factors which partly overlap or (CDCP1, MMP-10). Our findings highlight involved immune regulation, cell activation/migration, blood-brain barrier disruption, extracellular matrix abnormalities psychosis people, consistent role inflammation dysfunction pathogenesis disorders.

Язык: Английский

Процитировано

0
Exercise4Psychosis: A randomised control trial assessing the effect of moderate-to-vigorous exercise on inflammatory biomarkers and negative symptom profiles in men with first-episode psychosis DOI Creative Commons
Connor Dunleavy, Richard J. Elsworthy, Stephen J. Wood

и другие.

Brain Behavior and Immunity, Год журнала: 2024, Номер 120, С. 379 - 390

Опубликована: Июнь 19, 2024

First-Episode Psychosis (FEP) is a devastating mental health condition that commonly emerges during early adulthood, and characterised by disconnect in perceptions of reality. Current evidence suggests inflammation perturbed immune responses are involved the pathology FEP may be associated specifically with negative symptoms. Exercise training potent anti-inflammatory stimulus can reduce persistent inflammation, improve mood profiles general populations. Therefore, exercise represent novel adjunct therapy for FEP. The aim this study was to assess effect on biomarkers symptoms psychosis, physiological markers

Язык: Английский

Процитировано

0
Depressive and negative symptoms in the early and established stages of schizophrenia: integrating structural brain alterations, cognitive performance, and plasma interleukin-6 levels DOI Creative Commons
Fabiana Corsi‐Zuelli, Gary Donohoe, Siân Lowri Griffiths

и другие.

Biological Psychiatry Global Open Science, Год журнала: 2024, Номер 5(2), С. 100429 - 100429

Опубликована: Дек. 2, 2024

Depressive and negative symptoms are related to poor functional outcomes in schizophrenia. Cognitive deficits, reduced brain cortical thickness volumes, inflammation may contribute depressive symptoms, but pharmacological treatment disease progression confound the associations. We evaluated whether higher plasma interleukin 6 (IL-6) levels would be associated with more severe or schizophrenia explored illness stage utilizing early (BeneMin [Benefit of Minocycline on Negative Symptoms Psychosis: Extent Mechanism], n = 201, 72.8% male) established (iRELATE [Immune Response & Social Cognition Schizophrenia], 94, 67.3% cohorts. Using structural equation modeling a subsample (iRELATE: 42, 69.0% male; BeneMin: 102, 76.5% data metrics (cortical volume), general cognitive performance, IL-6 levels, we assessed interrelationships between these variables symptom severity samples combined only. All analyses were adjusted for sex, age, chlorpromazine equivalent dose. Higher (p < .05) .05). Structural findings only showed that interrelationship metrics, performance did not predict > lower Our results indicate differently dependent stage. Future work identifying elevated larger allow stratification personalized intervention by subgroups who at risk outcomes.

Язык: Английский

Процитировано

0
Study protocol for A randomized controlled trial with Rituximab for Psychotic disorder in adults (RCT-Rits) DOI Creative Commons

Susanne Bejerot,

Daniel Eklund, Hugo Hesser

и другие.

Research Square (Research Square), Год журнала: 2023, Номер unknown

Опубликована: Окт. 6, 2023

Abstract Background: The role of inflammation in the aetiology schizophrenia has gained wide attention and research on association shows an exponential growth last 15 years. Autoimmune diseases severe infections are risk factors for later development schizophrenia, elevated inflammatory markers childhood or adolescence associated with a greater adulthood, individuals have increased levels pro-inflammatory cytokines compared to healthy controls, autoimmune overrepresented schizophrenia. However, treatments anti-inflammatory agents so far doubtful clinical relevance. primary objective this study is test whether monoclonal antibody rituximab, directed against B-cell antigen CD20 ameliorates psychotic symptoms adults schizoaffective disorder examine potential mechanisms. A secondary characteristics inflammation-associated psychosis identify pre-treatment biochemical rituximab responders. third interview subset patients informants their experiences trial obtain insights that rating scales may not capture. Methods: proof-of-concept employing randomised, parallel-group, double-blind, placebo-controlled design testing effect depletion psychosis. 120 participants diagnosis spectrum disorders (SSD) (ICD-10 codes F20, F25) will receive either one intravenous infusion (1000 mg) saline. Psychiatric measures blood samples be collected at baseline, week 12, 24 post-infusion. Brief assessments also made weeks 2 7. Neuroimaging lumbar puncture, both optional, performed baseline endpoints. Approximately 40 interviewed qualitative analyses perceived changes well-being emotional qualities, addition views research. Discussion: This first RCT investigating add-on treatment unselected SSD patients. If helpful, it transform disorders. It heighten awareness immune-psychiatric reduce stigma. Trial registration: NCT05622201, EudraCT-nr 2022-000220-37 version 2.1. registered 14 th October 2022.

Язык: Английский

Процитировано

0